Journal Cover: Immunofluorescence microscopy of human adipose-derived stromal vascular fraction (SVF), identifying cellular components (blue – DAPI), leukocytes (red – CD45) and stromal/vascular progenitor cells (green – CD34). Courtesy of Dr. Severiano Dos Anjos, Ph.D; the GID group.
CellR4 (Cellular Repair, Replacement, Regeneration & Reprogramming – e-ISSN: 2329-7042, Verduci International; Editor-in-Chief: Camillo Ricordi, MD, FNAI) is a multidisciplinary, open access, peer-reviewed, online articles related to the field of Regenerative Medicine.
The aim of CellR4 (the Official Journal of The Cure Alliance) is to publish rigorously peer-reviewed articles to advance the knowledge in the field of regenerative medicine, spanning from fundamental new discoveries in basic science to translational research (“bench-to-bedside”), methods and protocols, clinical trials, and identification of novel therapeutic targets. CellR4 also serves as a trusted and authoritative platform aimed to discuss challenges and opportunities on the path to development, delivery and clinical application of novel therapeutic options for a wide range of chronic degenerative diseases. Topics covered by the journal include, but are not limited to, cell-based therapies, organ replacement therapies, solid organ and cell transplantation, tissue engineering, cellular reprogramming mechanisms and technologies, and regenerative pharmacology.
Articles are published on an ongoing basis through a continuous publication model. Articles are posted online as soon as they have completed the production process in a fully citable form associated with a universal digital object identifier (DOI). All full-text articles published in CellR4 are freely available to readers.
CellR4 is currently indexed in the following research databases and networks: , EBSCO catalogue, DOAJ, CNKI, TrendMD, Google Scholar, Semantic Scholar and Publons. More than 100 articles published in CellR4 by Authors funded by National Institutes of Health (NIH) have already been indexed in MEDLINE/PubMed.
COVID-19 and impact on peer review
As a result of the severe disruption to health care services that is being caused by the COVID-19 pandemic on a global scale, we are aware that many scientists and researchers will experience difficulty in meeting the timelines associated with our peer review process during normal times. We acknowledge that COVID-19 pandemic has led to changes in research priorities for many scientists and practitioners. Therefore, we intend to be highly flexible at this time.
Call for papers on COVID-19
We encourage scientists from all around the world to submit their research regarding COVID-19 in order to provide insights into the cellular basis for SARS-CoV-2 infection and the potential of cell-based therapies and novel regenerative medicine approaches for the treatment of COVID-19. We will expedite the publication of accepted manuscripts related to COVID-19. All content will be freely available to readers.